Merck Takes Strategic Stake in Evaxion to Advance AI-Driven Vaccine Discovery

Key Facts

Reflecting the accelerating adoption of advanced technologies in the healthcare sector, Merck & Company has disclosed a significant stake in Evaxion A/S, a firm specializing in AI-driven immunology. According to reports, Merck has decided to in-license the EVX-B3 vaccine candidate, which was discovered through Evaxion's proprietary AI platform. This move aims to leverage digital immunology platforms to streamline and enhance the credibility of the vaccine discovery and development process.

This strategic investment serves as a validation of AI-driven biotech pipelines by a mega-cap peer, which is positive for long-term R&D dynamics. While the immediate financial impact on Merck is expected to be limited, the partnership underscores a broader industry trend of pharmaceutical giants integrating digital solutions to reduce the time and cost of drug development. Per market data, such collaborations are increasingly seen as essential for maintaining a competitive edge in complex therapeutic areas.

Shares of Merck (MRK) stood at $152.22 at the close of August 19, 2026, having traded between a day high of $153.47 and a low of $144.9. With no major upcoming catalysts in the economic calendar specifically targeting the pharmaceutical sector in the immediate seven-day window, investors will likely focus on the progress of the EVX-B3 candidate and the integration of AI capabilities as long-term value drivers.